Common causes include gallstones, excessive alcohol consumption, certain medications, hypertriglyceridaemia, and anatomical abnormalities
Effects typically become more pronounced as the dose increases during the 16-week titration period, with peak appetite control often occurring around weeks 16-20 of treatment
Individual variation in GLP-1 receptor expression and gastrointestinal motility explains why one person tolerates a dose easily while another experiences significant symptoms at the same level
The virus can lead to severe liver damage if left untreated.
Berberine users sometimes report digestive upset (bloating, diarrhea, constipation), which can overlap with common GLP-1 side effects like nausea and appetite changes
Researchers used propensity score matching to match 9,193 adults using tirzepatide with 9,192 adults using semaglutide